LinkedIn
WebsiteBluejay Diagnostics Inc Overview
Bluejay Diagnostics Inc (NASDAQ: BJDX) is a public medical diagnostics company headquartered in Acton, Massachusetts. Founded in 2015, the company develops near-patient biomarker detection systems designed for triage, diagnosis, and monitoring of disease progression. Its lead product candidate, the Symphony™ platform, combines traditional ELISA methodology with microfluidics and nanotechnology to deliver quantitative clinical chemistry results.
Corporate Structure
Bluejay Diagnostics operates with a workforce of approximately 11–50 employees. The company’s leadership team includes founders Svetlana Dey and Indraneil Dey, who established the business to address the need for cost-effective, point-of-care testing in critical care settings. As a public company listed on NASDAQ, Bluejay Diagnostics complies with SEC reporting requirements and maintains an organizational structure focused on research and development.
Symphony platform by Markus Spiske
Recent Developments and News
On June 3, 2025, Bluejay Diagnostics issued a mid-year business and corporate update outlining its progress on the Symphony platform and operational milestones. On April 15, 2025, an abstract detailing the Symphony IL-6 Test was accepted for presentation at the Society of Academic Emergency Medicine Annual Meeting in Philadelphia, scheduled for May 13–16, 2025. Earlier on April 7, 2025, the company completed a warrant inducement transaction, generating approximately $3.7 million in gross proceeds to support ongoing development.
In the past quarter, Bluejay filed multiple Form 8-K reports:
- August 11, 2025 (Items 7.01 and 9.01)
- August 15, 2025 (Item 8.01)
- October 9, 2025 (Items 1.01, 7.01, and 9.01)
These filings include corporate disclosures and exhibit updates in compliance with SEC regulations.
Financial and Strategic Analysis
As of October 9, 2025, BJDX shares closed at $4.01, reflecting a one-day gain of 114.44% on a volume of 17,463,463 shares. The stock was trading near the lower end of its 52-week range and below its 200-day simple moving average. Key financial metrics from CNN Markets include:
| Metric | Value |
|---|---|
| Market capitalization | $2.79 million |
| Net income (fiscal year) | -$7.72 million |
| Net income (Q2) | -$1.96 million |
| Earnings per share (fiscal year) | -$114.19 |
| Earnings per share (Q2) | -$1.41 |
The warrant inducement transaction in April strengthened the company’s cash position to advance research and development as well as regulatory activities. Continued acceptance of scientific abstracts, such as the SAEM presentation, underscores the strategic emphasis on the Symphony IL-6 Test for inflammatory biomarker detection.
Market Position and Industry Context
Bluejay Diagnostics operates in the Health Technology sector within the Medical Specialties group, targeting infectious disease, inflammation, and oncology markets. Its Symphony platform—currently for research use only and not FDA cleared—offers a “sample-to-result” format that minimizes technician intervention. By enabling rapid, cost-effective testing at the point of care, the company aims to support hospitals, clinics, and long-term acute care facilities.
tl;dr
On October 9, 2025, BJDX shares rose to $4.01 with a 114.44% increase in trading volume. The company raised $3.7 million through a warrant inducement transaction on April 7, 2025, and secured an abstract acceptance for its Symphony IL-6 Test at the SAEM meeting in May 2025. Bluejay Diagnostics filed multiple Form 8-K reports this year, maintaining regulatory compliance. The near-patient Symphony platform is in development for potential FDA authorization.
